FLASCO

FLASCO News

Home » Current News & Publications » FLASCO News

FLASCO Prior Authorization Webinar

On April 17th, FLASCO’s Administrator Network hosted a webinar to discuss the challenges faced by practices when dealing with Prior Authorizations. We were joined by Risë Cleland, who presented Practical Strategies: The Challenge of Prior Authorization Burdens . Following Risë’s presentation, a panel representing different types of oncology practices in Florida, provided further insight on the topic. ...

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

 The Opdivo + low-dose Yervoy combination is the first and only treatment to show significantly superior overall survival versus sunitinib in intermediate- and poor-risk advanced renal cell carcinoma, including a survival benefit regardless of PD-L1 expression 1,2 Treatment with Opdivo + Yervoy delivered higher objective response rates, including more complete responses, than sunitinib 1,2 In the CheckMate -214 trial, which used dosing optimized for advanced renal...

FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma

On April 16, 2018, the Food and Drug Administration granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb Co.) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC...

FCS Foundation Honors Founding Chair Brad Prechtl and Announces New Board Leadership

Sarasota, FL – April 11th, 2018… The Florida Cancer Specialists (FCS) Foundation Board is pleased to announce new Board Co-Chairs, Dr. Michael Diaz, and FCS Board Member Jeffrey Phipps, Sr., as well as welcome new board member, FCS Physician Dr. Maen Hussein. Founding Chair, Brad Prechtl, was honored for his remarkable service to the Board and his contributions to the FCS...

FLASCO Fellow: Making a Difference in Patient’s Lives

As a senior fellow, one is blessed to have a light call schedule compared with that of our younger peers. Having paid our dues during residency and fellowship, we get the privilege of picking our call schedules and are required to cover just 4 weekends for the whole year. With 3 call weekends left on...

FDA approves everolimus for tuberous sclerosis complex-associated partial-onset seizures

On April 10, 2018, the Food and Drug Administration approved everolimus tablets for oral suspension (Afinitor Disperz, Novartis Pharmaceuticals Corp.) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell...

clovis oncology

FDA approves Clovis Oncology’s rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer

On April 6, 2018, the Food and Drug Administration approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Approval was based on ARIEL3 (NCT01968213), a randomized, double-blind,...

Charles Williams Jr., MD

It is with saddened hearts that we share with you the passing of FLASCO member and beloved and respected oncologist, Charles Williams Jr., MD. Dr. Williams has been a part of Moffitt Cancer Center since it opened its doors back in 1986. Dr. Williams was a committed physician who exemplified their mission and touched the...

FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia

On March 29, 2018, the Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Approval was based on the open...

FLORIDA CANCER SPECIALISTS FOUNDATION HOSTS RECORD-BREAKING POLO BRUNCH

Wellington, FL – March 26th, 2018… The Florida Cancer Specialists (FCS) Foundation is proud to announce the second annual Polo Brunch event, which was held on March 4th, 2018 at the International Polo Club Palm Beach, set an event record, raising $135,000, with all proceeds going to theFCS Foundation. This year, the event was chaired by Linda and Jeffrey...

Nilotinib Approved to Treat Pediatric Patients with Leukemia

The FDA approved an expanded indication for nilotinib (Tasigna) as a first- and second-line treatment for pediatric patients 1 year and older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP), according to a press release. Nilotinib is currently indicated to treat both adults and pediatric patients with newly-diagnosed Ph+ CML-CP. It is...

Dr. Janice Eakle Co-Authors Study on Triple Negative Breast Cancer

Lakewood Ranch, FL – March 22, 2018…… Dr. Janice Eakle, who practices at Florida Cancer Specialists (FCS) locations in Sarasota andLakewood Ranch, was a co-author of an article about a Phase II study that investigated the use of the drug enzalutamide in treating triple negative breast cancer (TNBC).  Published in the Journal of Clinical Oncology in January 2018, the study examined the anti-tumor...

MSI Service Evaluation

The Medicare Administrative Contractor (MAC) Satisfaction Indicator is the best way to share your opinion on their service directly to the Centers for Medicare & Medicaid Services. This survey should only take about 10 minutes of your time and helps them understand how they can better serve you. To take this survey, please CLICK HERE>>

bayer health

NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC

The NCCN guidelines were updated. CRC now includes the new dose escalation for Stivarga as a result of the ReDos study.  Read more at OncLive.com here http://www.onclive.com/web-exclusives/nccn-recommends-regorafenib-dose-escalation-in-metastatic-crc.

FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy

The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. “Today’s approval represents an improvement in the initial treatment regimens of advanced Hodgkin lymphoma that were introduced into clinical practice more than 40 years ago,”...

Sylvester Comprehensive Cancer Center Celebrates 1,000th Stem Cell Transplant

Recently more than 100 Sylvester patients, family members, faculty and staff shared their stories at the “Celebration of 1,000 Stem Cell Transplants,” marking a milestone in the growth of one of the nation’s largest adult stem cell transplant programs. FLASCO Member, Dr. Stephen D. Nimer, Sylvester Director welcomed everyone to the third annual celebration. He...

FMA 2018 Legislative Report

The 2018 Florida Legislative Session concluded on Sunday, March 11, with only 200 bills passed by both chambers and sent to Gov. Rick Scott. The FMA succeeded in getting Direct Primary Care legislation passed, and we secured important changes in the opioid bill for the benefit of physicians and their patients who suffer from acute...

Dr. Michael Diaz Co-Authors ASCO Special Article That Helps Guide National Health Care Policy on Use of Biosimilars in Oncology

St. Petersburg, FL – March 15, 2018……Florida Cancer Specialists (FCS) Director of Patient Advocacy Dr. Michael Diaz, who practices at two FCS locations in St. Petersburg, co-authored a Special Health Care Policy article on biosimilar medications sanctioned by the American Society of Clinical Oncology (ASCO). Published February 2018 in the Journal of Clinical Oncology, the article contributes to national policy development...

FDA Approves sBLA Updating Nivolumab Dosing Schedule Across Indications

On March 6, Bristol-Myers Squibb announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the nivolumab (Opdivo) dosing schedule to include 480 mg infused every 4 weeks for a majority of approved indications. This approval will provide health-care professionals the flexibility to customize patient care with the option of using the...

Dr. Andrew Lipman Co-Author of Phase 2 Study on Bendamustine, Bortezomib, Rituximab Combination for Low Grade Lymphoma

Naples, FL – March 1, 2018…… Dr. Andrew Lipman, who practices at Florida Cancer Specialists (FCS) in Bonita Springs and Naples West offices, was a co-author of a research paper evaluating the safety and efficacy of combining three drug agents – bendamustine, bortezomib and rituximab (BBR) – in patients with previously untreated low-grade lymphoma. Published January 2018 in the British Journal of Haematology,...

Eli Lilly and Company

FDA Approval of New Indication for Verzenio™

February 26, 2018 – The US Food and Drug Administration (FDA) approved a new indication for Verzenio™ (abemaciclib 50, 100, 150, 200 mg tablets). See below for the Indication and Important Safety Information and click to access the full Prescribing Information for Verzenio.    Dosing Regimen Tablet Strength Quantity NDC* Days of Therapy per Pack Verzenio 7-Day Dose...

Florida Cancer Specialists & Research Institute Welcomes Dr. Adewale A. Fawole

Lake & Sumter Counties, FL – March 1, 2018. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Adewale Fawole, MD, has joined the practice as a hospitalist and will be seeing FCS patients who require hospitalization. FCS CEO Brad Prechtl, MBA said, “Dr. Fawole will...

FDA approves Lilly’s abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer

On February 26, 2018, the Food and Drug Administration approved abemaciclib (VERZENIO™, Eli Lilly and Company) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Approval was based on MONARCH 3, a randomized (2:1), double-blinded,...

2nd Annual Polo Brunch Benefits Florida Cancer Specialists Foundation

Wellington, FL – February 20th, 2018… The Florida Cancer Specialists (FCS) Foundation is pleased to announce that the 2nd Annual Polo Brunch will be chaired by Linda and Jeffrey Phipps, Sr., including Honorary Chairs and FCS physicians, Drs. Elizabeth Byron, Todd Gersten, Daniel Spitz, Raul Storey and Sumithra Vattigunta-Gopal. The event will be held on March 4th, 2018, from 1:00 p.m. to 5:30 p.m. at the International Polo Club...

FLASCO VP, Dr. Raez, Published in NEJM

With admiration and excitement, FLASCO is proud to share Dr. Luis Raez’s, great accomplishment! Dr. Raez co-authored the article, Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. This is Dr. Raez’ second co-authored article to be published in The New England Journal of Medicine. Dr. Raez is Vice President of the Florida...

Who’s Online

There are no users currently online